148 related articles for article (PubMed ID: 14997914)
1. Short-term prophylactic prevention of post-ERCP pancreatitis.
Masci E; Mariani A
Gastrointest Endosc; 2003 Nov; 58(5):816. PubMed ID: 14997914
[No Abstract] [Full Text] [Related]
2. Somatostatin bolus injection for post-ERCP pancreatitis prevention: a need for further study.
Rudin D
Gastrointest Endosc; 2008 Jan; 67(1):190; author reply 190-1. PubMed ID: 18155442
[No Abstract] [Full Text] [Related]
3. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Xiong GS; Wu SM; Zhang XW; Ge ZZ
Braz J Med Biol Res; 2006 Jan; 39(1):85-90. PubMed ID: 16400468
[TBL] [Abstract][Full Text] [Related]
4. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
[TBL] [Abstract][Full Text] [Related]
5. Post-ERCP pancreatitis.
Arata S; Takada T; Hirata K; Yoshida M; Mayumi T; Hirota M; Yokoe M; Hirota M; Kiriyama S; Sekimoto M; Amano H; Wada K; Kimura Y; Gabata T; Takeda K; Kataoka K; Ito T; Tanaka M
J Hepatobiliary Pancreat Sci; 2010 Jan; 17(1):70-8. PubMed ID: 20012323
[TBL] [Abstract][Full Text] [Related]
6. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.
Ueki T; Otani K; Kawamoto K; Shimizu A; Fujimura N; Sakaguchi S; Matsui T
J Gastroenterol; 2007 Feb; 42(2):161-7. PubMed ID: 17351806
[TBL] [Abstract][Full Text] [Related]
7. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G
JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials.
Rudin D; Kiss A; Wetz RV; Sottile VM
J Gastroenterol Hepatol; 2007 Jul; 22(7):977-83. PubMed ID: 17559376
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.
Andriulli A; Solmi L; Loperfido S; Leo P; Festa V; Belmonte A; Spirito F; Silla M; Forte G; Terruzzi V; Marenco G; Ciliberto E; Sabatino A; Monica F; Magnolia MR; Perri F
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):713-8. PubMed ID: 15290665
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Andriulli A; Leandro G; Federici T; Ippolito A; Forlano R; Iacobellis A; Annese V
Gastrointest Endosc; 2007 Apr; 65(4):624-32. PubMed ID: 17383459
[TBL] [Abstract][Full Text] [Related]
11. Rectal indomethacin or intravenous gabexate mesylate as prophylaxis for acute pancreatitis post-endoscopic retrograde cholangiopancreatography.
Guglielmi V; Tutino M; Guerra V; Giorgio P
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(22):5268-5274. PubMed ID: 29228444
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials.
Chiu YJ; Chen SC; Kang YN; Hou SK; Chao CC; Chang CC
J Formos Med Assoc; 2021 Apr; 120(4):1090-1099. PubMed ID: 33183879
[TBL] [Abstract][Full Text] [Related]
13. Protease inhibitors for prevention of ERCP pancreatitis: can we afford the price of success?
Ziebert JJ; Bjorkman DJ
Am J Gastroenterol; 1997 Jun; 92(6):1067-8. PubMed ID: 9177543
[No Abstract] [Full Text] [Related]
14. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB
Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632
[TBL] [Abstract][Full Text] [Related]
15. Prevention of post-ERCP pancreatitis.
Haber GB
Gastrointest Endosc; 2000 Jan; 51(1):100-3. PubMed ID: 10625814
[No Abstract] [Full Text] [Related]
16. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
Andriulli A; Leandro G; Niro G; Mangia A; Festa V; Gambassi G; Villani MR; Facciorusso D; Conoscitore P; Spirito F; De Maio G
Gastrointest Endosc; 2000 Jan; 51(1):1-7. PubMed ID: 10625786
[TBL] [Abstract][Full Text] [Related]
17. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial.
Poon RT; Yeung C; Liu CL; Lam CM; Yuen WK; Lo CM; Tang A; Fan ST
Gut; 2003 Dec; 52(12):1768-73. PubMed ID: 14633959
[TBL] [Abstract][Full Text] [Related]
18. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.
Lee KT; Lee DH; Yoo BM
Pancreas; 2008 Nov; 37(4):445-8. PubMed ID: 18953260
[TBL] [Abstract][Full Text] [Related]
19. Antiproteases in preventing post-ERCP acute pancreatitis.
Tsujino T; Kawabe T; Omata M
JOP; 2007 Jul; 8(4 Suppl):509-17. PubMed ID: 17625308
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
Masci E; Cavallini G; Mariani A; Frulloni L; Testoni PA; Curioni S; Tittobello A; Uomo G; Costamagna G; Zambelli S; Macarri G; Innocenti P; Dragonetti C;
Am J Gastroenterol; 2003 Oct; 98(10):2182-6. PubMed ID: 14572565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
